Lopinavir – Page 12 – Communicable Diseases Research

Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline

코로나바이러스 질환 2019(COVID-19)로 입원한 성인 관리: 유럽 호흡기 학회 생활 지침

Practice Guideline

Published on 2021-04-152022-09-11
Journal: The European Respiratory Journal [Category] Fulltext, MERS, meta-analysis,

Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial

중증 COVID-19에서 인터페론 요법의 역할: COVIFERON 무작위 대조 시험

Randomized Controlled Trial

Published on 2021-04-132022-08-13
Journal: Scientific Reports [Category] MERS, SARS, 바이오마커, 임상, 치료제,

[키워드] 95% CI adverse events Arm assigned benefit Chest CT scans clinical Clinical improvement clinical seven-step ordinal scale ClinicalTrials.gov, NCT04343768 conducted control group Controlled trial CT scan defined discharge Effect Enrollment FIVE Hydroxychloroquine IFNs IFNα IFNβ IFNβ1a IFNβ1b improvement indicated individually-randomized injection intention-to-treat population interferon interferons intervention group laboratory-confirmed SARS-CoV-2 infection Lopinavir Lopinavir/ritonavir median Mortality NCT04343768 no significant difference no significant differences Open-label Ordinal Scale P-value Patient positive positive RT-PCR Previous studies previous study primary outcome measure randomization Randomized controlled trial Randomly reduction in Registration registration number Respiratory tract diseases Ritonavir role SARS-COV-2 infection Seven severely ill patient significant difference single dose subcutaneous injections therapeutic therapy time Trial Registration Number TTCI twice a day type 1 interferon type 1 interferons Viral viral infections
[DOI] 10.1038/s41598-021-86859-y PMC 바로가기 [Article Type] Randomized Controlled Trial

Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2

Molecular Biosciences

Published on 2021-04-092022-10-31
Journal: Frontiers in Molecular Biosciences [Category] COVID-19,

[키워드] analyses Analysis analyzed Antiviral can be used Compound compounds conditions confirmed COVID-19 case COVID-19 determine develop docked complex drug resistance dynamic Ebola virus disease Efficacy Emergency use high affinity higher affinity identify in vitro in vivo inhibiting initial screening interactions Lopinavir molecular mutant mutant protein Mutation mutations novel P323L mutation performed Potential Protein RdRP RdRp mutations RdRp protein Remdesivir Repurposed drugs residues SARS-CoV-2 SARS-CoV-2 variant Screening Seven tested the disease Treatment variants of SARS-CoV-2 Virtual screening virus
[DOI] 10.3389/fmolb.2021.645216 PMC 바로가기 [Article Type] Molecular Biosciences

SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study

이중 표적 TMPRSS2 및 ACE2에 의한 SARS-CoV-2 진입 억제제: 실리코 약물 용도 변경 연구

Article

Published on 2021-04-052022-09-11
Journal: European journal of pharmacology [Category] SARS, 신약개발, 치료제,

[키워드] ACE2 Alvimopan Analysis angiotensin Antiviral approved drug arbekacin clinically coronavirus disease COVID-19 COVID-19 pandemic docked docking score docking scores docking tool droplets drug drug treatment drugs Efficacy entry inhibitors FDA-approved drugs fleroxacin help homology modelling Host Human human Angiotensin-converting enzyme Human angiotensin-converting enzyme 2 human population human populations in silico in vitro in vivo inhibitor Lopinavir molecular molecular docking molecular dynamics molecular dynamics simulations nasal outcomes repurposing SARS-CoV-2 SARS-CoV-2 entry selected Serine target targets the vaccine TMPRSS2 transmembrane serine protease transmembrane serine protease 2 Treatment US-FDA valrubicin
[DOI] 10.1016/j.ejphar.2021.173922 PMC 바로가기 [Article Type] Article

Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies

재활용된 COVID-19 약물과 폐암 약물 요법의 잠재적 약물 상호 작용

Review

Published on 2021-04-012022-08-31
Journal: Archives of medical research [Category] MERS, SARS, 신약개발, 치료제,

[키워드] adverse outcomes anti-cancer treatment Azithromycin cancer patient Care ceftriaxone Chemotherapy Chloroquine Comorbidity Complication concomitant treatment concomitant treatments COVID-19 COVID-19 infection COVID-19 pandemic Dexamethasone dissemination drug Drug interactions drug-drug interaction Drug-drug interactions Famotidine Favipiravir Healthcare professional healthcare professionals history of smoking Hydroxychloroquine identification identify Immunosuppression information kinase inhibitors Lopinavir Lopinavir/ritonavir lung cancer lung cancer patient lung cancer patients malignancy management medication medications occur oseltamivir outcome Patient pharmacotherapy Potential Prophylactic proportion QT prolongation rationale receiving recent Remdesivir reported Reporting Repurposed drug ribavirin risk risk factor Ritonavir sarilumab severity smoking Tocilizumab tyrosine tyrosine kinase inhibitors umifenovir with COVID-19
[DOI] 10.1016/j.arcmed.2020.11.006 PMC 바로가기 [Article Type] Review

Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19

Observational Study

Published on 2021-04-012023-07-11
Journal: Journal of clinical pharmacy and therapeutics [Category] SARS,

[키워드] COVID-19 Favipiravir Lopinavir
[DOI] 10.1111/jcpt.13305 [Article Type] Observational Study

Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19

간 손상은 COVID-19 환자의 불리한 임상 결과와 독립적으로 연관되어 있습니다

Article

Published on 2021-04-012022-09-11
Journal: Gut [Category] SARS, 치료제,

[키워드] 95% CI acute respiratory syndrome adjusted Admission admitted to ICU age Alanine alanine aminotransferase albumin ALT/AST aspartate Aspartate aminotransferase AST Beta Biochemistry cholestasis Clinical outcome coronavirus disease Coronavirus disease 2019 Corticosteroid Corticosteroids COVID-19 COVID-19 patient COVID-19 patients database death defined diabete diabetes Diagnosis died HCoV HCoVs Hepatitis Hong Kong human coronavirus hypertension ICU Injury intensive care intensive care unit interferon interferon beta Invasive mechanical ventilation limit liver Liver function Liver function test Liver injury Lopinavir Lopinavir-ritonavir men occurred Patient patients patients with COVID-19 primary end point retrospective cohort study ribavirin Ritonavir SARS patient SARS patients Severe acute respiratory syndrome Virological
[DOI] 10.1136/gutjnl-2020-321726 PMC 바로가기 [Article Type] Article

Neglecting Plasma Protein Binding in COVID-19 Patients Leads to a Wrong Interpretation of Lopinavir Overexposure

COVID-19 환자에서 혈장 단백질 결합을 무시하면 Lopinavir 과다 노출에 대한 잘못된 해석으로 이어집니다

Article

Published on 2021-04-012022-09-11
Journal: Clinical Pharmacology and Therapeutics [Category] SARS, 치료제,

[키워드] acute respiratory syndrome albumin binding C reactive protein change changes in collected Concentration coronavirus disease Coronavirus disease 2019 COVID-19 Critical described description dose France glycoprotein high risk in some Infectious disease Inflammation inhibitory effect intensive care unit intensive care units International investigated Lopinavir Lopinavir/ritonavir medical record medical records metabolism Patient patients patients hospitalized patients with COVID-19 patients with HIV performed plasma concentration plasma protein Plasma Protein Binding Protein Protein binding recalled reduce reduction reported retrospective cohort study Ritonavir routine care SARS-CoV-2 Severe acute respiratory syndrome severe COVID-19 Total treat treated university Viral load were measured
[DOI] 10.1002/cpt.2196 PMC 바로가기 [Article Type] Article

Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra

Favipiravir 또는 Kaletra로 치료 7일 후 COVID-19 환자의 혈청 사이토카인 수치

Observational Study

Published on 2021-04-012022-09-11
Journal: International immunopharmacology [Category] SARS, 임상, 치료제,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Admission age Anti-viral therapy Antiviral antiviral therapy Antiviral treatment antiviral treatments baseline baseline level baseline levels Blood level blood levels C-reactive protein C-reactive protein (CRP cause change Chest computed tomography Computed tomography coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient CRP CT scan cytokine cytokine level Cytokine storm Cytokines Cytokines storm death elevated evaluated Evidence Favipiravir Flow flow cytometry healthy control healthy controls healthy subject healthy subjects IFNγ IL-1β IL-6 IL-8 inflammatory phase intensive care intensive care unit interferon interleukin interleukin-6 Kaletra laboratory-confirmed Laboratory-confirmed COVID-19 Lactate lactate dehydrogenase LDH Lopinavir Lopinavir/ritonavir lung Lung inflammation manifestation Necrosis observational study occurred Patient reduced retrospective Ritonavir SARS-CoV-2 serum serum cytokine serum cytokines Serum level serum levels severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe COVID-19 severe COVID-19 patients significantly subject subjects Supportive treatment suppress therapy TNFα Treatment Tumor tumor necrosis tumor necrosis factor was obtained
[DOI] 10.1016/j.intimp.2021.107407 PMC 바로가기 [Article Type] Observational Study

Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis

COVID-19 입원 환자에서 약물의 임상 효과: 체계적인 검토 및 메타 분석

Meta-Analysis

Published on 2021-03-252022-09-10
Journal: Therapeutic Advances in Respiratory Disease [Category] 치료제,

[키워드] Analysis antivirals article benefit Chloroquine clinical clinical effectiveness Clinical improvement conducted convalescent plasma country COVID-19 COVID-19 infection COVID-19 pandemic data extraction databases Dexamethasone diagnosis of SARS-CoV-2 drug drugs duration of hospitalization Effectiveness hospitalized patient hospitalized patients Hydroxychloroquine Infection Lopinavir Meta-analysis Mortality outcome oxygen oxygen support patients treated randomized clinical trial randomized clinical trials reduce mortality reduction Remdesivir resources retrieved risk Ritonavir SARS-CoV-2 SARS-COV-2 infection severe adverse events standard care systematic review Treatment Ventilation virological clearance with COVID-19
[DOI] 10.1177/17534666211007214 PMC 바로가기 [Article Type] Meta-Analysis